{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:04:35Z","timestamp":1780452275265,"version":"3.54.1"},"reference-count":78,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>When discontinuing benzodiazepines, treating withdrawal symptoms can be challenging. Some anti-seizure medications (ASM) may mitigate withdrawal symptoms. This article reviews the literature regarding adjunctive ASM use during benzodiazepine tapering and discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A PubMed search focusing on the use of ASMs as adjunctive agents to mitigate benzodiazepine withdrawal symptoms was conducted. Key search teams identified relevant articles, and the references of included articles were evaluated to identify potential additional publications for inclusion. In total, 21 articles met the inclusion criteria, and 44 articles were excluded for various reasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Several clinical trials, observational studies, case reports, and case series were identified. Carbamazepine was more effective than placebo at 3 months (74% benzodiazepine free vs 52% for placebo). Oxcarbazepine enabled successful rapid detoxification with minimal withdrawal symptoms in a small, noncontrolled study. Valproate, pregabalin, and gabapentin showed improvements in benzodiazepine-free rates, but the results were inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Evidence for ASM in benzodiazepine withdrawal is limited, emphasizing the need for provider discretion. Additional larger clinical trials are warranted to identify optimal agents to mitigate withdrawal symptoms and enhance successful benzodiazepine cessation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.9740\/mhc.2026.06.141","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:42:05Z","timestamp":1780364525000},"page":"141-149","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of adjunctive anti-seizure medications to facilitate chronic benzodiazepine discontinuation"],"prefix":"10.9740","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4862-5044","authenticated-orcid":true,"given":"Michael R.","family":"Dueno","sequence":"first","affiliation":[{"name":"University of Kentucky College of Pharmacy, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-2521","authenticated-orcid":true,"given":"Gavin T.","family":"Howington","sequence":"additional","affiliation":[{"name":"(Corresponding author) Associate Professor & Emergency Medicine Pharmacist, University of Kentucky College of Pharmacy, and University of Kentucky HealthCare, Lexington, Kentucky, gavin.howington@uky.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2098-3775","authenticated-orcid":true,"given":"Melody","family":"Ryan","sequence":"additional","affiliation":[{"name":"Professor, University of Kentucky College of Pharmacy, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"1","key":"i2168-9709-16-3-141-b01","series-title":"Behav Res Ther","first-page":"1","article-title":"Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse","volume":"43","author":"Morin","year":"2005","unstructured":"Morin CM,\nB\u00e9langer L,\nBastien C,\nValli\u00e8res A. Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther. 2005;43(1):1-14. DOI: 10.1016\/j.brat.2003.12.002"},{"issue":"2","key":"i2168-9709-16-3-141-b02","series-title":"Br J Clin Pharmacol","first-page":"285","article-title":"Benzodiazepine dependence and its treatment with low dose flumazenil","volume":"77","author":"Hood","year":"2014","unstructured":"Hood SD,\nNorman A,\nHince DA,\nMelichar JK,\nHulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77(2):285-94. DOI: 10.1111\/bcp.12023"},{"key":"i2168-9709-16-3-141-b03","series-title":"Ther Adv Psychopharmacol","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey","volume":"12","author":"Reid Finlayson","year":"2022","unstructured":"Reid Finlayson AJ,\nMacoubrie J,\nHuff C,\nFoster DE,\nMartin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey. Ther Adv Psychopharmacol. 2022;12. DOI: 10.1177\/20451253221082386"},{"key":"i2168-9709-16-3-141-b04","series-title":"Joint clinical practice guideline on benzodiazepine tapering: considerations when benzodiazepine risks outweigh benefits","author":"American Society of Addiction Medicine","year":"2025","unstructured":"American Society of Addiction Medicine. Joint clinical practice guideline on benzodiazepine tapering: considerations when benzodiazepine risks outweigh benefits. American Society of Addiction Medicine; 2025."},{"key":"i2168-9709-16-3-141-b05","series-title":"EClinicalMedicine","first-page":"102507","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review","volume":"70","author":"Brandt","year":"2024","unstructured":"Brandt J,\nBressi J,\nL\u00ea ML,\nNeal D,\nCadogan C,\nWitt-Doerring J, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024;70:102507. DOI: 10.1016\/j.eclinm.2024.102507"},{"issue":"10","key":"i2168-9709-16-3-141-b06","series-title":"Arch Gen Psychiatry","first-page":"908","article-title":"Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper","volume":"47","author":"Schweizer","year":"1990","unstructured":"Schweizer E,\nRickels K,\nCase WG,\nGreenblatt DJ. Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-15. DOI: 10.1001\/archpsyc.1990.01810220024003"},{"issue":"5","key":"i2168-9709-16-3-141-b07","series-title":"Pract Diabetes Int","first-page":"205","article-title":"Carbamazepine","volume":"27","author":"Harkin","year":"2010","unstructured":"Harkin G,\nHopkinson H. Carbamazepine. Pract Diabetes Int. 2010;27(5):205-6. DOI: 10.1002\/pdi.1485"},{"issue":"1","key":"i2168-9709-16-3-141-b08","series-title":"Epilepsia","first-page":"83","article-title":"Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures","volume":"50","author":"Zheng","year":"2009","unstructured":"Zheng T,\nClarke AL,\nMorris MJ,\nReid CA,\nPetrou S,\nO\u2019Brien TJ. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia. 2009;50(1):83-7. DOI: 10.1111\/j.1528-1167.2008.01759.x"},{"issue":"4","key":"i2168-9709-16-3-141-b09","series-title":"Alcohol Alcohol","first-page":"319","article-title":"A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention","volume":"35","author":"Harris","year":"2000","unstructured":"Harris JT,\nRoache JD,\nThornton JE. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention. Alcohol Alcohol. 2000;35(4):319-23. DOI:10.1093\/alcalc\/35.4.319"},{"issue":"5","key":"i2168-9709-16-3-141-b10","series-title":"Anaesthesia","first-page":"451","article-title":"Gabapentin: pharmacology and its use in pain management","volume":"57","author":"Rose","year":"2002","unstructured":"Rose MA,\nKam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57(5):451-62. DOI: 10.1046\/j.0003-2409.2001.02399.x"},{"issue":"2","key":"i2168-9709-16-3-141-b11","series-title":"Psychiatry Investig","first-page":"55","article-title":"Does pregabalin have neuropsychotropic effects?: a short perspective","volume":"6","author":"Marks","year":"2009","unstructured":"Marks DM,\nPatkar AA,\nMasand PS,\nPae CU. Does pregabalin have neuropsychotropic effects?: a short perspective. Psychiatry Investig. 2009;6(2):55-8. DOI: 10.4306\/pi.2009.6.2.55"},{"key":"i2168-9709-16-3-141-b12","series-title":"StatPearls [Internet]","article-title":"Physiology, GABA","author":"Jewett","year":"2024","unstructured":"Jewett BE,\nSharma S. Physiology, GABA. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"9","key":"i2168-9709-16-3-141-b13","series-title":"Nat Rev Drug Discov","first-page":"685","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","unstructured":"Rudolph U,\nKnoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685-97. DOI: 10.1038\/nrd3502"},{"issue":"3","key":"i2168-9709-16-3-141-b14","series-title":"Cochrane Database Syst Rev","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","unstructured":"Baandrup L,\nEbdrup BH,\nRasmussen J\u00d8,\nLindschou J,\nGluud C,\nGlenth\u00f8j BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3(3):CD011481. DOI: 10.1002\/14651858.CD011481.pub2"},{"issue":"2","key":"i2168-9709-16-3-141-b15","series-title":"J Geriatr Psychiatry Neurol","first-page":"106","article-title":"The use of carbamazepine to treat benzodiazepine withdrawal in a geriatric population","volume":"4","author":"Swantek","year":"1991","unstructured":"Swantek SS,\nGrossberg GT,\nNeppe VM,\nDoubek WG,\nMartin T,\nBender JE. The use of carbamazepine to treat benzodiazepine withdrawal in a geriatric population. J Geriatr Psychiatry Neurol. 1991;4(2):106-9. DOI: 10.1177\/089198879100400209"},{"issue":"4","key":"i2168-9709-16-3-141-b16","series-title":"Am J Psychiatry","first-page":"536","article-title":"Carbamazepine treatment for benzodiazepine withdrawal","volume":"146","author":"Ries","year":"1989","unstructured":"Ries RK,\nRoy-Byrne PP,\nWard NG,\nNeppe V,\nCullison S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146(4):536-7. DOI: 10.1176\/ajp.146.4.5362929759"},{"issue":"3","key":"i2168-9709-16-3-141-b17","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"145","article-title":"Treatment of benzodiazepine withdrawal symptoms with carbamazepine","volume":"241","author":"Garcia-Borreguero","year":"1991","unstructured":"Garcia-Borreguero D,\nBronisch T,\nApelt S,\nYassouridis A,\nEmrich HM. Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci. 1991;241(3):145-50. DOI: 10.1007\/BF02219713"},{"issue":"5","key":"i2168-9709-16-3-141-b18","series-title":"Arch Gen Psychiatry","first-page":"448","article-title":"Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome","volume":"48","author":"Schweizer","year":"1991","unstructured":"Schweizer E,\nRickels K,\nCase WG,\nGreenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48(5):448-52. DOI: 10.1001\/archpsyc.1991.01810290060012"},{"issue":"12","key":"i2168-9709-16-3-141-b19","series-title":"Am J Psychiatry","first-page":"1760","article-title":"Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine","volume":"151","author":"Klein","year":"1994","unstructured":"Klein E,\nColin V,\nStolk J,\nLenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 1994;151(12):1760-6. DOI: 10.1176\/ajp.151.12.17607977882"},{"issue":"5","key":"i2168-9709-16-3-141-b20","series-title":"a case report. Pharmacopsychiatry","first-page":"222","article-title":"Scheme-based benzodiazepine detoxification with oxcarbazepine","volume":"38","author":"Croissant","year":"2005","unstructured":"Croissant B,\nGrosshans M,\nKlein O,\nDiehl A,\nMann K. Scheme-based benzodiazepine detoxification with oxcarbazepine \u2013 a case report. Pharmacopsychiatry. 2005;38(5):222-3. DOI: 10.1055\/s-2005-873158"},{"issue":"5","key":"i2168-9709-16-3-141-b21","series-title":"Am J Drug Alcohol Abuse","first-page":"534","article-title":"Oxcarbazepine in rapid benzodiazepine detoxification","volume":"34","author":"Croissant","year":"2008","unstructured":"Croissant B,\nGrosshans M,\nDiehl A,\nMann K. Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse. 2008;34(5):534-40. DOI: 10.1080\/00952990802149021"},{"issue":"2","key":"i2168-9709-16-3-141-b22","series-title":"J Neuropsychiatry Clin Neurosci","first-page":"232","article-title":"Treatment of panic disorder and benzodiazepine withdrawal with valproate","volume":"3","author":"McElroy","year":"1991","unstructured":"McElroy SL,\nKeck PE Jr,\nLawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;3(2):232-3. DOI: 10.1176\/jnp.3.2.232-a"},{"issue":"7","key":"i2168-9709-16-3-141-b23","series-title":"Am J Psychiatry","first-page":"950","article-title":"Sodium valproate in benzodiazepine withdrawal","volume":"147","author":"Apelt","year":"1990","unstructured":"Apelt S,\nEmrich HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry. 1990;147(7):950-1. DOI: 10.1176\/ajp.147.7.950a2113360"},{"issue":"1","key":"i2168-9709-16-3-141-b24","series-title":"Heroin Addict Relat Clin Probl","first-page":"15","article-title":"Effect of valproate on benzodiazepine withdrawal severity in opioid-dependent subjects: a pilot study","volume":"13","author":"Vorma","year":"2011","unstructured":"Vorma H,\nKatila H. Effect of valproate on benzodiazepine withdrawal severity in opioid-dependent subjects: a pilot study. Heroin Addict Relat Clin Probl. 2011;13(1):15-20."},{"issue":"1","key":"i2168-9709-16-3-141-b25","series-title":"Psychopharmacology (Berl","first-page":"1","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome","volume":"141","author":"Rickels","year":"1999","unstructured":"Rickels K,\nSchweizer E,\nGarcia Espa\u00f1a F,\nCase G,\nDeMartinis N,\nGreenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl). 1999;141(1):1-5. DOI: 10.1007\/s002130050798"},{"issue":"4","key":"i2168-9709-16-3-141-b26","series-title":"J Psychiatr Pract","first-page":"310","article-title":"A retrospective study of the adjunctive use of gabapentin with benzodiazepines for the treatment of benzodiazepine withdrawal","volume":"28","author":"Leung","year":"2022","unstructured":"Leung E,\nNgo DH,\nEspinoza JA Jr,\nBeal LL,\nChang C,\nBaris DA, et al. A retrospective study of the adjunctive use of gabapentin with benzodiazepines for the treatment of benzodiazepine withdrawal. J Psychiatr Pract. 2022;28(4):310-8. DOI: 10.1097\/pra.0000000000000639"},{"issue":"3","key":"i2168-9709-16-3-141-b27","series-title":"Am J Drug Alcohol Abuse","first-page":"333","article-title":"Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients","volume":"42","author":"Mariani","year":"2016","unstructured":"Mariani JJ,\nMalcolm RJ,\nMamczur AK,\nChoi JC,\nBrady R,\nNunes E,\nLevin FR. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am J Drug Alcohol Abuse. 2016;42(3):333-40. DOI: 10.3109\/00952990.2015.1125493"},{"issue":"6","key":"i2168-9709-16-3-141-b28","series-title":"Pharmacopsychiatry","first-page":"292","article-title":"Pregabalin in benzodiazepine withdrawal","volume":"40","author":"Biermann","year":"2007","unstructured":"Biermann T,\nBleich S,\nKornhuber J,\nHillemacher T. Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry. 2007;40(6):292-3. DOI: 10.1055\/s-2007-992146"},{"issue":"2","key":"i2168-9709-16-3-141-b29","series-title":"Int Clin Psychopharmacol","first-page":"110","article-title":"Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series","volume":"23","author":"Oulis","year":"2008","unstructured":"Oulis P,\nMasdrakis VG,\nKarakatsanis NA,\nKarapoulios E,\nKouzoupis AV,\nKonstantakopoulos G, et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol. 2008;23(2):110-2. DOI: 10.1097\/YIC.0b013e3282f2b4b2"},{"issue":"4","key":"i2168-9709-16-3-141-b30","series-title":"Eur Psychiatry","first-page":"301","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice","volume":"27","author":"Bobes","year":"2012","unstructured":"Bobes J,\nRubio G,\nTer\u00e1n A,\nCervera G,\nL\u00f3pez-G\u00f3mez,\nVilardaga I,\nP\u00e9rez M. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry. 2012;27(4):301-7. DOI: 10.1016\/j.eurpsy.2010.12.004"},{"issue":"4","key":"i2168-9709-16-3-141-b31","series-title":"J Psychopharmacol","first-page":"461","article-title":"Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial","volume":"26","author":"Hadley","year":"2012","unstructured":"Hadley SJ,\nMandel FS,\nSchweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461-70. DOI: 10.1177\/0269881111405360"},{"issue":"1-3","key":"i2168-9709-16-3-141-b32","series-title":"Eur J Pharmacol","first-page":"101","article-title":"The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice","volume":"439","author":"Lamberty","year":"2002","unstructured":"Lamberty Y,\nGower AJ,\nKlitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol. 2002;439(1-3):101-6. DOI: 10.1016\/s0014-2999(02)01409-7"},{"issue":"2","key":"i2168-9709-16-3-141-b33","series-title":"J Addict Med","first-page":"230","article-title":"The use of a single dose of phenobarbital for inpatient management of benzodiazepine withdrawal: a case report","volume":"17","author":"Messinger","year":"2023","unstructured":"Messinger JC,\nHakimi E,\nVercollone L. The use of a single dose of phenobarbital for inpatient management of benzodiazepine withdrawal: a case report. J Addict Med. 2023;17(2):230-2. DOI: 10.1097\/adm.0000000000001071"},{"issue":"1","key":"i2168-9709-16-3-141-b34","series-title":"J Subst Abuse Treat","first-page":"55","article-title":"Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers","volume":"7","author":"Ravi","year":"1990","unstructured":"Ravi NV,\nMaany I,\nBurke WM,\nDhopesh V,\nWoody GE. Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers. J Subst Abuse Treat. 1990;7(1):55-8. DOI: 10.1016\/0740-5472(90)90036-p"},{"issue":"3","key":"i2168-9709-16-3-141-b35","series-title":"Arch Gen Psychiatry","first-page":"270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","unstructured":"Anand A,\nCharney DS,\nOren DA,\nBerman RM,\nHu XS,\nCappiello A,\nKrystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270-6. DOI: 10.1001\/archpsyc.57.3.270"},{"issue":"11","key":"i2168-9709-16-3-141-b36","series-title":"Neuropharmacology","first-page":"2139","article-title":"The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro","volume":"39","author":"Cunningham","year":"2000","unstructured":"Cunningham MO,\nJones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology. 2000;39(11):2139-46. DOI: 10.1016\/s0028-3908(00)000514"},{"issue":"5","key":"i2168-9709-16-3-141-b37","series-title":"Hum Psychopharmacol","first-page":"375","article-title":"Topiramate in benzodiazepine withdrawal","volume":"18","author":"Cheseaux","year":"2003","unstructured":"Cheseaux M,\nMonnat M,\nZullino DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol. 2003;18(5):375-7. DOI: 10.1002\/hup.497"},{"issue":"4","key":"i2168-9709-16-3-141-b38","series-title":"World J Biol Psychiatry","first-page":"265","article-title":"Topiramate use in alprazolam addiction","volume":"7","author":"Michopoulos","year":"2006","unstructured":"Michopoulos I,\nDouzenis A,\nChristodoulou C,\nLykouras L. Topiramate use in alprazolam addiction. World J Biol Psychiatry. 2006;7(4):265-7. DOI: 10.1080\/15622970600671036"},{"issue":"7","key":"i2168-9709-16-3-141-b39","series-title":"Neuropharmacology","first-page":"907","article-title":"Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro","volume":"45","author":"Cunningham","year":"2003","unstructured":"Cunningham MO,\nWoodhall GL,\nJones RS. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology. 2003;45(7):907-17. DOI:10.1016\/S0028-3908(03)00270-3"},{"issue":"1","key":"i2168-9709-16-3-141-b01","series-title":"Behav Res Ther","first-page":"1","article-title":"Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse","volume":"43","author":"Morin","year":"2005","unstructured":"Morin CM,\nB\u00e9langer L,\nBastien C,\nValli\u00e8res A. Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther. 2005;43(1):1-14. DOI: 10.1016\/j.brat.2003.12.002"},{"issue":"2","key":"i2168-9709-16-3-141-b02","series-title":"Br J Clin Pharmacol","first-page":"285","article-title":"Benzodiazepine dependence and its treatment with low dose flumazenil","volume":"77","author":"Hood","year":"2014","unstructured":"Hood SD,\nNorman A,\nHince DA,\nMelichar JK,\nHulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77(2):285-94. DOI: 10.1111\/bcp.12023"},{"key":"i2168-9709-16-3-141-b03","series-title":"Ther Adv Psychopharmacol","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey","volume":"12","author":"Reid Finlayson","year":"2022","unstructured":"Reid Finlayson AJ,\nMacoubrie J,\nHuff C,\nFoster DE,\nMartin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an internet survey. Ther Adv Psychopharmacol. 2022;12. DOI: 10.1177\/20451253221082386"},{"key":"i2168-9709-16-3-141-b04","series-title":"Joint clinical practice guideline on benzodiazepine tapering: considerations when benzodiazepine risks outweigh benefits","author":"American Society of Addiction Medicine","year":"2025","unstructured":"American Society of Addiction Medicine. Joint clinical practice guideline on benzodiazepine tapering: considerations when benzodiazepine risks outweigh benefits. American Society of Addiction Medicine; 2025."},{"key":"i2168-9709-16-3-141-b05","series-title":"EClinicalMedicine","first-page":"102507","article-title":"Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review","volume":"70","author":"Brandt","year":"2024","unstructured":"Brandt J,\nBressi J,\nL\u00ea ML,\nNeal D,\nCadogan C,\nWitt-Doerring J, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024;70:102507. DOI: 10.1016\/j.eclinm.2024.102507"},{"issue":"10","key":"i2168-9709-16-3-141-b06","series-title":"Arch Gen Psychiatry","first-page":"908","article-title":"Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper","volume":"47","author":"Schweizer","year":"1990","unstructured":"Schweizer E,\nRickels K,\nCase WG,\nGreenblatt DJ. Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-15. DOI: 10.1001\/archpsyc.1990.01810220024003"},{"issue":"5","key":"i2168-9709-16-3-141-b07","series-title":"Pract Diabetes Int","first-page":"205","article-title":"Carbamazepine","volume":"27","author":"Harkin","year":"2010","unstructured":"Harkin G,\nHopkinson H. Carbamazepine. Pract Diabetes Int. 2010;27(5):205-6. DOI: 10.1002\/pdi.1485"},{"issue":"1","key":"i2168-9709-16-3-141-b08","series-title":"Epilepsia","first-page":"83","article-title":"Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures","volume":"50","author":"Zheng","year":"2009","unstructured":"Zheng T,\nClarke AL,\nMorris MJ,\nReid CA,\nPetrou S,\nO\u2019Brien TJ. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia. 2009;50(1):83-7. DOI: 10.1111\/j.1528-1167.2008.01759.x"},{"issue":"4","key":"i2168-9709-16-3-141-b09","series-title":"Alcohol Alcohol","first-page":"319","article-title":"A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention","volume":"35","author":"Harris","year":"2000","unstructured":"Harris JT,\nRoache JD,\nThornton JE. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention. Alcohol Alcohol. 2000;35(4):319-23. DOI:10.1093\/alcalc\/35.4.319"},{"issue":"5","key":"i2168-9709-16-3-141-b10","series-title":"Anaesthesia","first-page":"451","article-title":"Gabapentin: pharmacology and its use in pain management","volume":"57","author":"Rose","year":"2002","unstructured":"Rose MA,\nKam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57(5):451-62. DOI: 10.1046\/j.0003-2409.2001.02399.x"},{"issue":"2","key":"i2168-9709-16-3-141-b11","series-title":"Psychiatry Investig","first-page":"55","article-title":"Does pregabalin have neuropsychotropic effects?: a short perspective","volume":"6","author":"Marks","year":"2009","unstructured":"Marks DM,\nPatkar AA,\nMasand PS,\nPae CU. Does pregabalin have neuropsychotropic effects?: a short perspective. Psychiatry Investig. 2009;6(2):55-8. DOI: 10.4306\/pi.2009.6.2.55"},{"key":"i2168-9709-16-3-141-b12","series-title":"StatPearls [Internet]","article-title":"Physiology, GABA","author":"Jewett","year":"2024","unstructured":"Jewett BE,\nSharma S. Physiology, GABA. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"9","key":"i2168-9709-16-3-141-b13","series-title":"Nat Rev Drug Discov","first-page":"685","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","unstructured":"Rudolph U,\nKnoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685-97. DOI: 10.1038\/nrd3502"},{"issue":"3","key":"i2168-9709-16-3-141-b14","series-title":"Cochrane Database Syst Rev","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","unstructured":"Baandrup L,\nEbdrup BH,\nRasmussen J\u00d8,\nLindschou J,\nGluud C,\nGlenth\u00f8j BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3(3):CD011481. DOI: 10.1002\/14651858.CD011481.pub2"},{"issue":"2","key":"i2168-9709-16-3-141-b15","series-title":"J Geriatr Psychiatry Neurol","first-page":"106","article-title":"The use of carbamazepine to treat benzodiazepine withdrawal in a geriatric population","volume":"4","author":"Swantek","year":"1991","unstructured":"Swantek SS,\nGrossberg GT,\nNeppe VM,\nDoubek WG,\nMartin T,\nBender JE. The use of carbamazepine to treat benzodiazepine withdrawal in a geriatric population. J Geriatr Psychiatry Neurol. 1991;4(2):106-9. DOI: 10.1177\/089198879100400209"},{"issue":"4","key":"i2168-9709-16-3-141-b16","series-title":"Am J Psychiatry","first-page":"536","article-title":"Carbamazepine treatment for benzodiazepine withdrawal","volume":"146","author":"Ries","year":"1989","unstructured":"Ries RK,\nRoy-Byrne PP,\nWard NG,\nNeppe V,\nCullison S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146(4):536-7. DOI: 10.1176\/ajp.146.4.5362929759"},{"issue":"3","key":"i2168-9709-16-3-141-b17","series-title":"Eur Arch Psychiatry Clin Neurosci","first-page":"145","article-title":"Treatment of benzodiazepine withdrawal symptoms with carbamazepine","volume":"241","author":"Garcia-Borreguero","year":"1991","unstructured":"Garcia-Borreguero D,\nBronisch T,\nApelt S,\nYassouridis A,\nEmrich HM. Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci. 1991;241(3):145-50. DOI: 10.1007\/BF02219713"},{"issue":"5","key":"i2168-9709-16-3-141-b18","series-title":"Arch Gen Psychiatry","first-page":"448","article-title":"Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome","volume":"48","author":"Schweizer","year":"1991","unstructured":"Schweizer E,\nRickels K,\nCase WG,\nGreenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48(5):448-52. DOI: 10.1001\/archpsyc.1991.01810290060012"},{"issue":"12","key":"i2168-9709-16-3-141-b19","series-title":"Am J Psychiatry","first-page":"1760","article-title":"Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine","volume":"151","author":"Klein","year":"1994","unstructured":"Klein E,\nColin V,\nStolk J,\nLenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 1994;151(12):1760-6. DOI: 10.1176\/ajp.151.12.17607977882"},{"issue":"5","key":"i2168-9709-16-3-141-b20","series-title":"a case report. Pharmacopsychiatry","first-page":"222","article-title":"Scheme-based benzodiazepine detoxification with oxcarbazepine","volume":"38","author":"Croissant","year":"2005","unstructured":"Croissant B,\nGrosshans M,\nKlein O,\nDiehl A,\nMann K. Scheme-based benzodiazepine detoxification with oxcarbazepine \u2013 a case report. Pharmacopsychiatry. 2005;38(5):222-3. DOI: 10.1055\/s-2005-873158"},{"issue":"5","key":"i2168-9709-16-3-141-b21","series-title":"Am J Drug Alcohol Abuse","first-page":"534","article-title":"Oxcarbazepine in rapid benzodiazepine detoxification","volume":"34","author":"Croissant","year":"2008","unstructured":"Croissant B,\nGrosshans M,\nDiehl A,\nMann K. Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse. 2008;34(5):534-40. DOI: 10.1080\/00952990802149021"},{"issue":"2","key":"i2168-9709-16-3-141-b22","series-title":"J Neuropsychiatry Clin Neurosci","first-page":"232","article-title":"Treatment of panic disorder and benzodiazepine withdrawal with valproate","volume":"3","author":"McElroy","year":"1991","unstructured":"McElroy SL,\nKeck PE Jr,\nLawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;3(2):232-3. DOI: 10.1176\/jnp.3.2.232-a"},{"issue":"7","key":"i2168-9709-16-3-141-b23","series-title":"Am J Psychiatry","first-page":"950","article-title":"Sodium valproate in benzodiazepine withdrawal","volume":"147","author":"Apelt","year":"1990","unstructured":"Apelt S,\nEmrich HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry. 1990;147(7):950-1. DOI: 10.1176\/ajp.147.7.950a2113360"},{"issue":"1","key":"i2168-9709-16-3-141-b24","series-title":"Heroin Addict Relat Clin Probl","first-page":"15","article-title":"Effect of valproate on benzodiazepine withdrawal severity in opioid-dependent subjects: a pilot study","volume":"13","author":"Vorma","year":"2011","unstructured":"Vorma H,\nKatila H. Effect of valproate on benzodiazepine withdrawal severity in opioid-dependent subjects: a pilot study. Heroin Addict Relat Clin Probl. 2011;13(1):15-20."},{"issue":"1","key":"i2168-9709-16-3-141-b25","series-title":"Psychopharmacology (Berl","first-page":"1","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome","volume":"141","author":"Rickels","year":"1999","unstructured":"Rickels K,\nSchweizer E,\nGarcia Espa\u00f1a F,\nCase G,\nDeMartinis N,\nGreenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl). 1999;141(1):1-5. DOI: 10.1007\/s002130050798"},{"issue":"4","key":"i2168-9709-16-3-141-b26","series-title":"J Psychiatr Pract","first-page":"310","article-title":"A retrospective study of the adjunctive use of gabapentin with benzodiazepines for the treatment of benzodiazepine withdrawal","volume":"28","author":"Leung","year":"2022","unstructured":"Leung E,\nNgo DH,\nEspinoza JA Jr,\nBeal LL,\nChang C,\nBaris DA, et al. A retrospective study of the adjunctive use of gabapentin with benzodiazepines for the treatment of benzodiazepine withdrawal. J Psychiatr Pract. 2022;28(4):310-8. DOI: 10.1097\/pra.0000000000000639"},{"issue":"3","key":"i2168-9709-16-3-141-b27","series-title":"Am J Drug Alcohol Abuse","first-page":"333","article-title":"Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients","volume":"42","author":"Mariani","year":"2016","unstructured":"Mariani JJ,\nMalcolm RJ,\nMamczur AK,\nChoi JC,\nBrady R,\nNunes E,\nLevin FR. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am J Drug Alcohol Abuse. 2016;42(3):333-40. DOI: 10.3109\/00952990.2015.1125493"},{"issue":"6","key":"i2168-9709-16-3-141-b28","series-title":"Pharmacopsychiatry","first-page":"292","article-title":"Pregabalin in benzodiazepine withdrawal","volume":"40","author":"Biermann","year":"2007","unstructured":"Biermann T,\nBleich S,\nKornhuber J,\nHillemacher T. Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry. 2007;40(6):292-3. DOI: 10.1055\/s-2007-992146"},{"issue":"2","key":"i2168-9709-16-3-141-b29","series-title":"Int Clin Psychopharmacol","first-page":"110","article-title":"Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series","volume":"23","author":"Oulis","year":"2008","unstructured":"Oulis P,\nMasdrakis VG,\nKarakatsanis NA,\nKarapoulios E,\nKouzoupis AV,\nKonstantakopoulos G, et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol. 2008;23(2):110-2. DOI: 10.1097\/YIC.0b013e3282f2b4b2"},{"issue":"4","key":"i2168-9709-16-3-141-b30","series-title":"Eur Psychiatry","first-page":"301","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice","volume":"27","author":"Bobes","year":"2012","unstructured":"Bobes J,\nRubio G,\nTer\u00e1n A,\nCervera G,\nL\u00f3pez-G\u00f3mez,\nVilardaga I,\nP\u00e9rez M. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry. 2012;27(4):301-7. DOI: 10.1016\/j.eurpsy.2010.12.004"},{"issue":"4","key":"i2168-9709-16-3-141-b31","series-title":"J Psychopharmacol","first-page":"461","article-title":"Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial","volume":"26","author":"Hadley","year":"2012","unstructured":"Hadley SJ,\nMandel FS,\nSchweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461-70. DOI: 10.1177\/0269881111405360"},{"issue":"1-3","key":"i2168-9709-16-3-141-b32","series-title":"Eur J Pharmacol","first-page":"101","article-title":"The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice","volume":"439","author":"Lamberty","year":"2002","unstructured":"Lamberty Y,\nGower AJ,\nKlitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol. 2002;439(1-3):101-6. DOI: 10.1016\/s0014-2999(02)01409-7"},{"issue":"2","key":"i2168-9709-16-3-141-b33","series-title":"J Addict Med","first-page":"230","article-title":"The use of a single dose of phenobarbital for inpatient management of benzodiazepine withdrawal: a case report","volume":"17","author":"Messinger","year":"2023","unstructured":"Messinger JC,\nHakimi E,\nVercollone L. The use of a single dose of phenobarbital for inpatient management of benzodiazepine withdrawal: a case report. J Addict Med. 2023;17(2):230-2. DOI: 10.1097\/adm.0000000000001071"},{"issue":"1","key":"i2168-9709-16-3-141-b34","series-title":"J Subst Abuse Treat","first-page":"55","article-title":"Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers","volume":"7","author":"Ravi","year":"1990","unstructured":"Ravi NV,\nMaany I,\nBurke WM,\nDhopesh V,\nWoody GE. Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers. J Subst Abuse Treat. 1990;7(1):55-8. DOI: 10.1016\/0740-5472(90)90036-p"},{"issue":"3","key":"i2168-9709-16-3-141-b35","series-title":"Arch Gen Psychiatry","first-page":"270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","unstructured":"Anand A,\nCharney DS,\nOren DA,\nBerman RM,\nHu XS,\nCappiello A,\nKrystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270-6. DOI: 10.1001\/archpsyc.57.3.270"},{"issue":"11","key":"i2168-9709-16-3-141-b36","series-title":"Neuropharmacology","first-page":"2139","article-title":"The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro","volume":"39","author":"Cunningham","year":"2000","unstructured":"Cunningham MO,\nJones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology. 2000;39(11):2139-46. DOI: 10.1016\/s0028-3908(00)000514"},{"issue":"5","key":"i2168-9709-16-3-141-b37","series-title":"Hum Psychopharmacol","first-page":"375","article-title":"Topiramate in benzodiazepine withdrawal","volume":"18","author":"Cheseaux","year":"2003","unstructured":"Cheseaux M,\nMonnat M,\nZullino DF. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol. 2003;18(5):375-7. DOI: 10.1002\/hup.497"},{"issue":"4","key":"i2168-9709-16-3-141-b38","series-title":"World J Biol Psychiatry","first-page":"265","article-title":"Topiramate use in alprazolam addiction","volume":"7","author":"Michopoulos","year":"2006","unstructured":"Michopoulos I,\nDouzenis A,\nChristodoulou C,\nLykouras L. Topiramate use in alprazolam addiction. World J Biol Psychiatry. 2006;7(4):265-7. DOI: 10.1080\/15622970600671036"},{"issue":"7","key":"i2168-9709-16-3-141-b39","series-title":"Neuropharmacology","first-page":"907","article-title":"Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro","volume":"45","author":"Cunningham","year":"2003","unstructured":"Cunningham MO,\nWoodhall GL,\nJones RS. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology. 2003;45(7):907-17. DOI:10.1016\/S0028-3908(03)00270-3"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/3\/article-p141.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/3\/article-p141.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/3\/article-p141.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:31:31Z","timestamp":1780450291000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/3\/article-p141.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2026.06.141","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}